CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
Key facts
- Who runs it
- REGENXBIO Inc.
- Where
- New Brunswick, Oakland, Philadelphia, and Pittsburgh, United StatesSee the 4 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 48 people, planned
- Started
- 27 Sept 2018
- Ended
- Aug 2025
- Type of study
- Interventional, 6 groups
- Treatments tested
- RGX-121
- Record updated
- 28 January 2025
Who can take part
- Age
- 4 months to 5 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Other criteria
- Part 1 Inclusion Criteria:
- The subject's legal guardian(s) is (are) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
- Is a male ≥4 months to < 5 years of age on Day 1
- Must meet any of the following criteria:; Has a documented diagnosis of MPS II and a has a neurocognitive testing score ≤ 77 (Bayley or Kaufman), OR; Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (Bayley or Kaufman) OR; Has a relative clinically diagnosed with severe MPS II who has the same IDS mutation as the subject AND in the opinion of a geneticist has inherited a severe form of MPS II OR; Has documented mutation (s) in IDS that in the opinion of a geneticist is always known to result in a neuronopathic phenotype AND in the opinion of a clinician has a severe form of MPS II; Part 2 Inclusion Criteria:
- The subject's legal guardian(s) is (are) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
- Is a male ≥4 months to < 5 years of age on Day 1
- Has a documented diagnosis of neuronopathic MPS II. Neuronopathic MPS II can be documented with any of the following methods:; Has a BSID-III Cognitive Composite score at or below -1 SD (85) from normative mean; Has two consecutive neurodevelopmental assessments that support a decline on MSEL visual receptive, expressive language, or fine motor, or BSID-III cognition, expressive language, or fine motor ≥ 1 SD on serial neurocognitive testing administered between 3 to 36 months apart; Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the subject AND the subject, in the opinion of a geneticist, has inherited a neuronopathic form of MPS II; Has documented mutation(s) in IDS known to result in a neuronopathic phenotype; Part 1 Exclusion Criteria:
- Has contraindications for intracisternal (IC) injection, intracerebroventricular (ICV) injection or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has a (cerebral) ventricular shunt that may impact the proper dosing of the subject
- Received hematopoietic stem cell transplantation
- Has had prior treatment with an AAV-based gene therapy product
- Received ELAPRASE® via intrathecal (IT) administration within 4 months of signing the ICF or experienced a serious hypersensitivity reaction to ELAPRASE®
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing the ICF, whichever is longer; Part 2 Exclusion Criteria:
- Has a contraindication for an IC injection, ICV injection or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has a (cerebral) ventricular shunt that may impact the proper dosing of the subject
- Received hematopoietic stem cell transplantation
- Has had prior treatment with an AAV-based gene therapy product
- Is receiving idursulfase (ELAPRASE®) via intrathecal (IT) administration, or a blood brain barrier-crossing enzyme replacement therapy. Subjects receiving IT ELAPRASE® or a blood brain barrier-crossing ERT may enroll if they agree to discontinue these therapies starting at least 3 months prior to dosing with RGX-121, and for the 24 months of follow-up
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing the ICF, whichever is longer
Where in United States
Also in 1 other country, 1 site
- St. Peter's University HospitalNew Brunswick, United States
- University of California San Francisco, Benioff Children's HospitalOakland, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare DisordersPittsburgh, United States
About the trial
What the trial wants to find out
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy, dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II.
The 6 groups in the trial
- Part 1: RGX-121 Dose 1Treatment being tested
1.3x10\^10 GC/g brain mass of RGX-121
Treatment: RGX-121
- Part 1: RGX-121 Dose 2Treatment being tested
6.5x10\^10 GC/g brain mass of RGX-121
Treatment: RGX-121
- Part 1: RGX-121 Dose 2 Expanded CohortTreatment being tested
6.5x10\^10 GC/g brain mass of RGX-121
Treatment: RGX-121
- Part 1: RGX-121 Dose 3Treatment being tested
2.0x10\^11 GC/g brain mass of RGX-121
Treatment: RGX-121
- Part 1: RGX-121 Dose 3 Expanded CohortTreatment being tested
2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay) equivalent to, 2.0x10\^11 GC/g brain mass of RGX-121 (Poly-A-specific PCR assay)
Treatment: RGX-121
- Part 2: RGX-121 Pivotal ExpansionTreatment being tested
2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay)
Treatment: RGX-121
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
- Record updated
- 28 January 2025